Cervical Cancer

Cervical cancer is the fourth most common cancer found in women globally, and it's primarily caused by persistent high-risk HPV infection. Cervical cancer, which develops in the tissues of the cervix, can be classified into two types: squamous cell carcinoma and adenocarcinoma. Several studies have led to the discovery of a range of biomarkers, including several polymorphisms, microRNAs, mRNA, and serum biomarkers. OriGene offers antibodies, plasmids, and recombinant proteins for the most prominent cervical cancer biomarkers.

Explore All Cervical Cancer Products

Potential biomarkers 1, 2, 3, 4

HPV E6-E7 ANXA2 ASF1B A1AT PYCR2 TTR ApoA-1 VDBP

Key genes mutated in cervical cancer 5

CASP8 ERBB3 HLA-A MED1 SHKBP1 TGFBR2

Other genes

PD-L1 PD-L2 KRAS ARID1A PTEN

One of the challenges in cervical cancer is to distinguish between squamous cell carcinoma (SCC) from adenocarcinoma (AEC) 6 In a recent study, Li et al. showed that a combination of cytokeratin 5/6 (CK5/6), p63, p40 and MUC5AC are useful in differentiating cervical adenocarcinoma from cervical squamous cell carcinoma using immunohistochemistry 7

CK5/6

CK5/6
Mesothelioma tissue stained for Cytokeratin 5 & 6 with mouse monoclonal antibody Cat # TA327667

p63

p63
Human Lung Carcinoma tissue stained for p63 with mouse monoclonal antibody Cat # TA802078

p40

p40-1.jpg
Human Tonsil stained for p40 with mouse monoclonal antibody Cat # TA592167

MUC5AC

MUC5AC
Human Stomach tissue stained for MUC5AC with mouse monoclonal antibody Cat # TA327703
Learn more about CK5/6 tools!
Learn more about p63 tools!
Learn more about p40 tools!
Learn more about MUC5AC tools!

Products for Cervical Cancer Research

Antibodies Plasmids Protein siRNA CRISPR Kit
p16INK4a TA500036S RC220937 TP320937 SR300743 KN411784
Ki-67 UM870033 RC220910 TP710117 SR302906 KN420910
Cyclin D1 TA801655S RC204957 TP304957 SR300410 KN404957
pRb TA805640 RC219911 TP319911 SR421213 KN412234
MCM2 UM800130 RC202506 TP313809 SR302840 KN402506
p53 TA502870S RC200003 TP300003 SR322075 KN200003
p63 TA802078S RC208013 TP308013 SR323296 KN408013
TOP2A TA802516 RC221568L4V SR322074 KN518059
OVCA1 TA340016 RC221955 TP321955 SR301256 KN421955
BCL-2 TA806591 RC204498 TP304498 SR300411 KN404498
BAX TA810334 RC204369 TP304369 SR300401 KN404369
CK8 TA500021 RC209570 TP309570 SR302611 KN409570
CK17 DM127-05 RC201619 AR51400PU-N SR302619 KN401619
CK19 TA500212 RC209707 TP309707 SR302621 KN409707
CK7 TA803077 RC201124 TP761431 SR302610 KN401124
MT1-MMP/MMP-14 TA368852 RC208917 TP308917 SR321000 KN408917
MMP-1 TA356169 RC202460 TP302460 SR302924 KN402460
MMP-9 AM06662SU-N RC202872 TP302872 SR513162 KN402872
Nanog TA302153 RC210243 AR39082PU-N SR312705 KN410243
ALDH1 UM500039 RC200723 TP300684 SR416114 KN400723

References:

  1. Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020 Jan 21;10:3116.
  2. Wang Z, Jiang C, Pang L, Jia W, Wang C, Gao X, Zhang X, Dang H, Ren Y. ANXA2 is a potential marker for the diagnosis of human cervical cancer. Biomark Med. 2021 Jan;15(1):57-67.
  3. Liu X, Song J, Zhang Y, Wang H, Sun H, Feng X, Hou M, Chen G, Tang Q, Ji M. ASF1B promotes cervical cancer progression through stabilization of CDK9. Cell Death Dis. 2020 Aug 26;11(8):705
  4. Keeratichamroen S, Subhasitanont P, Chokchaichamnankit D, Weeraphan C, Saharat K, Sritana N, Kantathavorn N, Wiriyaukaradecha K, Sricharunrat T, Paricharttanakul NM, Auewarakul C, Svasti J, Srisomsap C. Identification of potential cervical cancer serum biomarkers in Thai patients. Oncol Lett. 2020 Jun;19(6):3815-3826.
  5. Burk R. et al. The Cancer Genome Atlas Research Network., Nature 543, 378–384 (2017).
  6. Li H, Jing X, Yu J, et al. A combination of cytokeratin 5/6, p63, p40 and MUC5AC are useful for distinguishing squamous cell carcinoma from adenocarcinoma of the cervix. Diagn Pathol. 2020;15(1):104
  7. Ma Y et al. Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis. Thorac Cancer. 2015;6(3):288–95.